

Correction



Correction: The Synthetic α -Bromo-2',3,4,4'-Tetramethoxychalcone (α -Br-TMC) Inhibits the JAK/STAT Signaling Pathway

The *PLOS ONE* Staff

In Figure 5, some of the graphs are missing numbers on the y-axis. Please see the corrected Figure 5 here.

Citation: The *PLOS ONE* Staff (2014) Correction: The Synthetic α -Bromo-2',3,4,4'-Tetramethoxychalcone (α -Br-TMC) Inhibits the JAK/STAT Signaling Pathway. *PLoS ONE* 9(8): e105845. doi:10.1371/journal.pone.0105845

Published August 8, 2014

Copyright: © 2014 The *PLOS ONE* Staff. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Figure 5. α -Br-TMC exerts distinct effects in normal and cancer cells. Ba/F3 (A), its caSTAT5-transformed counterpart Ba/F3-1*6 (B) and human leukemic K562 (C) cells were treated 90 minutes with 0.2 μ M TSA, 10 μ M α -Br-TMC or 1 μ M Imatinib. Ba/F3 cells (A) were stimulated with 5 ng/mL IL-3 after an initial 30 minute drug pre-treatment (hence subjected to a 60 minute IL-3 stimulation). DMSO (vehicle) final concentration was adjusted to 0.02% in all conditions. Expression of STAT5-dependent (*Cis*, *Osm*, *c-Myc*, *Pim-1*) and -independent (*JunB*, *c-Fos*, *36b4*) genes was analyzed by quantitative RT-PCR. Gene expression data were normalized to mouse ribosomal *S9* (A, B) or to human Lamin A/C (*LMNA*) (C) housekeeping gene-encoded mRNAs. (A, B) Normalized data are presented with adjusted Y-axis scale for a direct comparison of mRNA levels in the respective normal and transformed Ba/F3 and Ba/F3-1*6 cell lines.

doi:10.1371/journal.pone.0090275.g005

Reference

1. Pinz S, Unser S, Brueggemann S, Besl E, Al-Rifai N, et al. (2014) The Synthetic α -Bromo-2',3,4,4'-Tetramethoxychalcone (α -Br-TMC) Inhibits the JAK/STAT Signaling Pathway. PLoS ONE 9(3): e90275. doi:10.1371/journal.pone.0090275